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1. Introduction
N-type voltage-gated calcium channel (Cav2.2) is a validated target for chronic pain 
treatment [10; 94; 96]. These channels underlie increased excitability and neurotransmission 
accompanying pathological conditions including neuropathic pain [15; 21; 66]. ω-conotoxin 
GVIA (Ziconotide/Prialt®) is a selective tonic blocker of the closed-state of CaV2.2 and is 
used clinically by the intrathecal route of administration to treat neuropathic pain [84]. The 
use of ziconotide, however, is encumbered by difficult dosing regimens, a very narrow 
therapeutic window, and numerous side effects including dizziness, nausea, nystagmus, 
memory impairment, and hallucinations [68; 75; 76; 82]. Nevertheless, the clinical efficacy 
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of ziconotide, supports the development of novel CaV2.2-targeted compounds with superior 
properties [49; 95].
We reported that collapsin response mediator protein 2 (CRMP2) interacts with CaV2.2 and 
enhances its functional activity [14; 19; 44; 86]. CBD3, a peptide from CRMP2, disengages 
CaV2.2 from CRMP2 to inhibit calcium influx, transmitter release and acute, inflammatory 
and neuropathic pain [13] [28]. In seeking to improve upon this novel allosteric antagonism, 
we tailored CBD3 peptides with antinociceptive efficacy in models of postoperative pain 
[29], and neuropathic pain induced by anti-retroviral drug treatment [13; 70], or focal nerve 
demyelination [89]. A mutant CBD3 peptide, where the 6th amino acid was changed from 
alanine to lysine, demonstrated suppression of nociceptor excitability and inhibition of not 
only N-, but also, T- and R-type Ca2+ channels and was efficacious in reversing neuropathic 
pain induced by anti-retroviral drug treatment [67]. Here, merging the pan-calcium channel 
inhibitory nature of the mutant peptide with the R9 motif, we created R9-CBD3-A6K.
To test the in vivo efficacy of R9-CBD3-A6K in mitigating nerve injury-induced neuropathic 
pain, a translatable output measure advanced by Porreca and group was applied [61; 93]. 
Assessment of ongoing pain has been challenging in nonverbal animals. Pain is aversive, 
producing strong motivational drive to escape or seek relief. We previously demonstrated 
that pairing a context with a treatment that effectively relieves ongoing pain produces 
preference for that context (i.e., conditioned place preference) through negative 
reinforcement. Removal of aversive states induced by ongoing pain by intrinsically non-
rewarding treatments (e.g., peripheral nerve block with lidocaine or intravenous ketorolac 
[62; 69; 93]) are accompanied by release of dopamine in the nucleus accumbens (NAc) shell 
representing the natural reward of pain relief. Thus, assessment of NAc dopamine release 
was proposed as an objective, neurochemical translational biomarker of pain relief [24; 62; 
69; 93]; this concept has been validated in post-surgical [61], cephalic [24], osteoarthritic 
[64], neuropathic [93], and cancer-induced bone [69] pain. Here, we tested if acute R9-
CBD3-A6K induces DA release from NAc in nerve-injured, but not naïve or sham-operated, 
animals. We also evaluated whether tolerance is observed to the pain relief following 
sustained administration of R9-CBD3-A6K, and assessed potential CNS side effects 
including impairment of memory retrieval, sensorimotor function, or depression. Our studies 
characterize R9-CBD3-A6K as a novel allosterically modulator of CaV channels, with 
therapeutic potential to treat severe neuropathic pain with an acceptable safety profile.
2. Methods
2.1. Animals
Pathogen-free, adult female Sprague-Dawley rats (initial weight 150–200 g; Harlan 
Laboratories, Houston, TX) were housed in temperature (23 ± 3°C) and light (12-h light: 12-
h dark cycle; lights on at 07:00 h) controlled rooms with standard rodent chow and water 
available ad libitum. There are very few studies using female animals in preclinical settings, 
despite many chronic pain conditions involving more female patients than male counterparts. 
The Institutional Animal Care and Use Committees of Indiana University/Purdue University 
in Indianapolis or the University of Arizona approved these experiments. All procedures 
were conducted in accordance with the Guide for Care and Use of Laboratory Animals 
Xie et al. Page 2
Pain. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
published by the National Institutes of Health, the ethical guidelines of the International 
Association for the Study of Pain. Study design followed the ARRIVE guidelines initially 
published by Journal of Pharmacology and Pharmacotherapeutics [45]. Animals were 
randomly assigned to treatment or control groups and experimenters were blinded to the 
grouping information until the analysis was completed.
2.2. Peptide, chemicals, and antibodies
R9-CBD3-A6K (RRRRRRRRRARSRLKELRGVPRGL) peptide was synthesized and 
HPLC-purified by Genscript Inc. (Piscataway, NJ). All chemicals, unless noted were 
purchased from Sigma (St. Louis, MO). Antibodies were purchased as follows: CRMP2 
(Cat# C2993, Sigma, St. Louis, MO) and CaV2.2 (TA308673, Origene Technologies, Inc, 
Rockville, MD).
2.3. CRMP2 protein purification
GST-CRMP2 protein was purified as previously described [14; 85]. Briefly, following an 19 
h long induction at 16°C with 0.5 mM IPTG, bacterial cells expressing recombinant 
CRMP2-GST were resuspended in 50 mM NaH2PO4, pH 7.5, 500 mM NaCl, 10% glycerol, 
0.5 mM TCEP, supplemented with Complete EDTA-free protease inhibitors (Roche, Basel, 
Switzerland). Disruption of the bacteria was performed by two rounds of high-pressure 
homogenization at 10,000 PSI with a LM10 microfluidizer (Microfluidics, Westwood), and 
the lysate was centrifuged 45 min at 4,500Xg at 4°C. The supernatant was loaded on a GST-
Trap HP column (GE Healthcare, Uppsala, Sweden) equilibrated with 50 mM HEPES pH 
7.5, 300 mM NaCl, 10% glycerol, and 0.5 mM TCEP. After a washing step with 50 mM 
HEPES pH 7.5, 300 mM NaCl, 10% glycerol, 0.5 mM TCEP, CRMP2-GST was eluted with 
a glutathione gradient. The fractions of interest for CRMP2-GST were loaded on a HiLoad 
Superdex size exclusion column (GE Healthcare, Uppsala, Sweden) and eluted with 50 mM 
NaH2PO4, pH 7.5 10% glycerol, 0.5 mM TCEP. The eluted proteins were concentrated with 
Amicon Ultra 15 centrifugal filters (Regenerated cellulose 10,000 NMWL; Merck Millipore, 
Darmstadt, Germany) and flash frozen on dry ice and stored at −80°C until use. Protein 
concentration was determined by a Pierce assay using bovine serum albumin (BSA) as a 
standard. The purity of the protein was verified with SDS-PAGE and structure/activity by 
checking its ability to bind tubulin (data not shown).
2.4. GST-pull-down and Western blotting
Lumbar segment of spinal cord lysates prepared from adult Sprague Dawley rats were 
generated by homogenization and sonication in RIPA buffer (50 mM Tris-HCl, pH 7.4, 50 
mM NaCl, 2 mM MgCl2, 1% (vol/vol) NP40, 0.5% (mass/vol) sodium deoxycholate, 0.1% 
(mass/vol) SDS). The RIPA buffer included freshly added protease inhibitors (Cat# B14002, 
Biotools, Houston, TX), phosphatase inhibitors (Cat# B15002, Biotools, Houston, TX), and 
Benzonase (Cat# 71206, Millipore, Billerica, MA). Protein concentrations were determined 
using the BCA protein assay (Cat# PI23225, Thermo scientific). Glutathione magnetic beads 
(Cat# B23702, Biotools, Houston, TX), pre-incubated with purified CRMP2-GST (~0.4 
μM), were incubated overnight with 300 μg of total protein from spinal cord lysates at 4°C 
in the absence or presence of the indicated peptides with gentle rotation. Beads were washed 
3 times with RIPA buffer before re-suspension in Laemmli buffer and denaturation (5 min at 
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95°C) and immunoblotting [12; 42; 90]. Immunoblots were revealed by enhanced 
luminescence (WBKLS0500, Millipore) before exposure to photographic film. Films were 
scanned, digitized, and quantified using Un-Scan-It gel version 6.1 scanning software (Silk 
Scientific Inc, Orem, UT).
2.5. Preparation of acutely dissociated dorsal root ganglion (DRG) neurons
DRGs from all levels were acutely dissociated using methods as described previously [29]. 
Briefly, DRGs were removed from naïve animals. The DRGs were treated with collagenase 
A and collagenase D in HBSS for 20 min (1 mg/ml; Roche Applied Science, Indianapolis, 
IN), followed by treatment with papain (30 U/ml, Worthington Biochemical, Lakewood, NJ) 
in HBSS containing 0.5 mM EDTA and cysteine at 35 C. The cells were then dissociated by 
mechanical trituration in culture media containing 1 mg/ml bovine serum albumin and 
trypsin inhibitor (Worthington Biochemical, Lakewood, NJ). The culture media was Ham’s 
F-12 mixture, DMEM, supplemented with 10% fetal bovine serum, penicillin and 
streptomycin (100 μg/ml and 100 U/ml) and N2 (Life Technologies). The cells were then 
plated on coverslips coated with poly-L lysine and laminin (BD bioscience) and incubated 
for 2–3 h before more culture media was added to the wells. The cells were then allowed to 
sit undisturbed for 12–15 h to adhere at 37° C (with 5% CO2).
2.6.1. Surface biotinylation on live DRGs in culture—Biotinylation was performed 
as described previously [12; 13; 41]. DRGs were processed for biotinylation experiments 48 
h post isoaltion. Briefly, live cells were incubated with sulfosuccinimidyl 2-(Biotinamido) 
Ethyl-1,3′Dithiopropionate (EZ-link Sulfo NHS-SS-biotin; 1 mg/mg protein, Pierce 
Biotechnology Inc., Rockland, IL) for 30 min at 4°C in cold PBS, pH 8.0. Excess biotin was 
quenched with PBS containing 100 mM glycine, washed 3× with ice-cold PBS and the pellet 
was resuspended in RIPA lysis buffer. The resuspended pellet was triturated 10× (25-gauge 
needle) and centrifuged at 100,000 × g for 20 min. The biotinylated proteins were separated 
from clear solubilizate by adsorption onto Streptavidin agarose beads (Novagen) for 2–4 h at 
4°C. Beads were washed 3–5× with RIPA buffer, and bound biotinylated proteins were 
gently eluted off the beads with RIPA buffer containing 2% Triton X-100 and 650 mM NaCl 
by end-over-end incubation for 1 h at 30°C. The biotinylated and total fractions were 
subjected to immunoblotting with β-tubulin and CaV2.2 antibodies.
2.6.2. Immunocytochemistry, confocal microscopy and colocalization analysis
—Immunocytochemistry was performed on DRGs incubated with vehicle (control) or 
peptide (30 μM) for 24 hr [14; 19; 29]. Briefly, cells were fixed using 4% paraformaldehyde, 
4% sucrose for 20 min at room temperature. Permeabilization was achieved by a 30 min 
incubation in phosphate buffered saline (PBS), 0.1% Triton X-100, following which non-
specific binding sites were saturated by PBS containing 3% bovine serum albumin for 30 
min at room temperature. Cell staining was performed with primary antibodies (CaV2.2 and 
CRMP2) in PBS with 3% BSA overnight at 4°C. The cells were then washed thrice in PBS, 
and incubated with PBS containing 3% BSA and secondary antibodies (Alexa 488 goat anti-
mouse and Alexa 594 goat anti-rabbit secondary antibodies (Life Technologies)) for 1 hr at 
room temperature. Coverslips were mounted and stored at 4°C until analysis. 
Immunofluorescent micrographs were acquired on a Ziess LSM 710 inverted upright 
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microscope using a 40X, 1.3 numerical aperture oil immersion objective or on a Nikon C1si 
scanning confocal microscope using CFI Plan APO VC 60× Oil immersion objective with 
1.4 numerical aperture. For all quantitative comparisons among cells under differing 
experimental conditions, camera gain and other relevant settings were kept constant. Nikon 
NIS-elements software was used for quantifying cellular membrane fluorescence. Membrane 
immunoreactivity was calculated by measuring the signal intensity in the area contiguous to 
the boundary of the cell. Annular regions of interest (ROI) were assigned to individual 
neurons. A perimeter of a neuron was manually traced, and then an inner curve was obtained 
at a constant distance from the perimeter. A region enclosed by the two curves represented 
the annular membrane ROI. All images were corrected for background by subtracting the 
average background fluorescence (areas within the field of view not containing cells) from 
the region of interest. Finally, co-localization analysis, including calculation of the Pearson’s 
correlation coefficient, was performed using the NIS-elements software.
2.7. Calcium imaging in acutely dissociated dorsal root ganglion neurons
DRG neurons were loaded at 37°C with 3 μM Fura-2AM (Kd=25 μM, λex 340, 380 nm/λemi 
512 nm) to follow changes in intracellular calcium ([Ca2+]c) in a standard bath solution 
containing 139 mM NaCl, 3 mM KCl, 0.8 mM MgCl2, 1.8 mM CaCl2, 10 mM NaHEPES, 
pH 7.4, 5 mM glucose exactly as previously described [13]. Fluorescence imaging was 
performed with an inverted microscope, Nikon Eclipse TE2000-U, using objective Nikon 
Super Fluor 20× 0.75 NA and a Photometrics cooled CCD camera CoolSNAPHQ (Roper 
Scientific, Tucson, AZ) controlled by MetaFluor 6.3 software (Molecular Devices, 
Downingtown, PA). The excitation light was delivered by a Lambda-LS system (Sutter 
Instruments, Novato, CA). The excitation filters (340 ± 5 and 380 ± 7) were controlled by a 
Lambda 10-2 optical filter change (Sutter Instruments). Fluorescence was recorded through 
a 505 nm dichroic mirror at 535 ± 25 nm. To minimize photobleaching and phototoxicity, 
the images were taken every ~5 seconds during the time-course of the experiment using the 
minimal exposure time that provided acceptable image quality. The changes in [Ca2+]c were 
monitored by following a ratio of F340/F380, calculated after subtracting the background 
from both channels.
2.8. Constellation pharmacology
These experiments were performed as described previously [57; 80], but with the following 
modifications. DRG neurons were loaded at 37°C with 3μM Fura-2AM for 30 minutes in 
Tyrode’s solution. After a 1 minute baseline measurement Ca2+ influx was stimulated by the 
addition of the following receptor agonists: 400 nM menthol, 50 μM histamine, 10 μM 
adenosine triphosphate (ATP), 200 μM allyl isothiocyanate (AITC), 1 mM acetylcholine 
(Ach), 100 nM capsaicin diluted in Tyrode’s solution (without TTX or Nifedipine). At the 
end of the constellation pharmacology protocol, cell viability was assessed by 
depolarization-induced Ca2+ influx using and an excitatory KCl solution comprised of 
32mM NaCl, 90mM KCl, 2mM MgCl2, 2mM CaCl2, 25mM HEPES, pH 7.4, 30mM 
glucose. After the 1-minute baseline measurement, each trigger was applied for 15-seconds 
in the order indicated above in 6-minute intervals. Following each trigger, bath solution was 
continuously perfused over the cells to wash off excess of the trigger. This process was 
automated using the software WinTask x64 (Version 5.1, WinTask) that controlled the 
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perfusion of the standard bath solution and triggers through Valvelink 8.2 software 
(Automate Scientific). For the R9-CBD3-A6K condition, 10-μM peptide was added to the 
Tyrode’s solution during the loading with Fura-2AM, as well as to each of the solutions 
containing a trigger. Fluorescence imaging was performed under the same conditions noted 
above for calcium imaging. A cell was defined as a ‘responder’ if its fluorescence ratio of 
340nm/380nm was greater than 10% of the baseline value calculated using the average 
fluorescence in the 30 seconds preceding application of the trigger.
2.9. Electrophysiology
2.9.1. Current clamp electrophysiology—Electrophysiology experiments were 
performed as described previously [67]. Sharp-electrode intracellular recordings were 
obtained from primary DRG neurons 12–18 h after dissociation. Coverslips were transferred 
to a recording chamber that was mounted on the stage of an inverted microscope (Nikon 
Eclipse Ti, Nikon Instruments Inc., Melville, NY). The chamber was perfused with a bath 
solution containing (mM): NaCl 120, KCl 3, CaCl2 1, MgCl2 1, HEPES 10, Glucose 10, 
adjusted to pH 7.4 and osmolarity 300 mosM. The recordings were obtained at room 
temperature. Intracellular recording electrodes were fabricated from borosilicate glass 
(World Precision Instruments, Sarasota, FL) and pulled on a Flaming/Brown micropipette 
puller (P-98, Sutter Instruments, Novato, CA). Electrodes were filled with 1.0 M KCl 
(impedance: 40–80 MΩ) and positioned by a micromanipulator (Newport Corporation, 
Irvine, CA). A −0.1 nA current injection was used to bridge-balance the electrode resistance. 
Electrophysiological recordings were performed with continuous current-clamp in bridge 
mode using an AxoClamp-2B amplifier, stored digitally via Digidata 1322A interface, and 
analyzed offline with pClamp 9 software (Axon Instruments, Union City, CA). A neuron 
was accepted for study only when it exhibited a resting membrane potential (RMP) more 
negative than −45 mV. For each neuron isolated for study, a continuous recording was 
obtained for 1 minute without the delivery of any external stimulus. Neuronal excitability of 
small (≤30 μm) and medium (31–45 μm) diameter dissociated DRG (lumbar) sensory 
neurons was measured by injecting 1-s current pulses into the soma every 30 s. Cell size was 
estimated during patch clamp experiments using an eyepiece micrometer and a 20× 
objective (Nikon Eclipse TE2000-U, using objective Nikon Super Fluor 20× 0.75 NA). At 
this magnification, one tick mark within the eyepeice micrometer is equivalent to 5.0 μm. 
Current was adjusted in order to elicit 1–2 action potentials per current injection under 
baseline conditions. Following 3 control current injections, R9-CBD3-A6K was applied to 
the coverslip and current injections continued every 30 s. Neuronal excitability was 
measured as number of action potentials elicited per current pulse before and immediately 
after addition of R9-CBD3-A6K (15 and 45 s, respectively).
2.9.2. Whole-cell voltage-clamp electrophysiology—Recordings were obtained from 
acutely dissociated DRG neurons as described [29]. To isolate calcium currents, Na+ and K+ 
currents were blocked with 500 nM tetrodotoxin (TTX; Alomone Laboratories) and 30 mM 
tetraethylammonium chloride (TEA-Cl; Sigma). Extracellular recording solution (at ~310 
mOsm) consisted of the following (in mM): 110 N-methyl-D-glucamine (NMDG), 10 
BaCl2, 30 TEA-Cl, 10 HEPES, 10 glucose, pH at 7.4, 0.001 TTX, 0.01 nifedipine. The 
intracellular recording solution (at ~310 mOsm) consisted of the following (in mM): 
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contained 150 CsCl2, 10 HEPES, 5 Mg-ATP, 5 BAPTA, pH at 7.4. Fire-polished recording 
pipettes, 2 to 5 MV resistances were used for all recordings. Whole-cell recordings were 
obtained with a HEKA EPC-10 USB (HEKA Instruments Inc.); data were acquired with a 
Patchmaster (HEKA) and analyzed with a Fitmaster (HEKA). Capacitive artifacts were fully 
compensated, and series resistance was compensated by ~70%. Recordings made from cells 
with greater than a 5 mV shift in series resistance compensation error were excluded from 
analysis. All experiments were performed at room temperature (~23°C). To isolate the 
contributions of particular channel subtypes, we used the following subunit-selective 
blockers (all purchased from Alomone Labs, Jerusalem): Nifedipine (10 μM, L-type); ω-
agatoxin GIVA (200 nM, P/Q-type) [56]; ω-conotoxin-GVIA (500 nM, N-type) [26]; 
SNX-482 (200 nM, R-type) [63]; and 3,5-dichloro-N-[1-(2,2-dimethyl-tetrahydro-pyran-4-
ylmethyl)-4-fluoro-piperidin-4-ylmethyl]-benzamide (TTA-P2, 1 μM, T-type) [20].
2.10. Tibial Nerve Injury (TNI)
Tibial nerve injury (TNI) was carried out to model nerve injury-induced neuropathic pain as 
described previously [42; 90]. Female Sprague-Dawley rats 150–200g were anesthetized 
using isoflurane (4% induction and 2% maintenance). The right sciatic nerve was isolated 
under aseptic surgical conditions by blunt dissection of the femoral biceps muscle, without 
damaging the epimycium. The sciatic nerve and its three branches were isolated: the sural, 
common peroneal and tibial nerves and only the tibial nerve was tightly-ligated with 5-0 silk 
and transected distal to the ligation. Additional 2–3 mm of distal nerve stump was removed 
to prevent re-innervation by the proximal nerve. The overlying muscle and skin was then 
sutured in two separate layers. Sham-injured animals were subjected to all preceding 
procedures with the exception of ligation and transection.
2.11. Assessment of tactile hypersensitivity
In experiments conducted in Tucson, the withdrawal threshold of the hindpaw was 
determined in response to probing with a series of eight calibrated von Frey filaments 
(Stoelting, Wood Dale, IL) in logarithmically spaced increments ranging from 0.41 to 15 gm 
(4–150 N). Each filament was applied perpendicularly to the plantar surface of the left 
hindpaw of rats kept in suspended wire-mesh cages (20 × 15 × 20 cm with ~5 mm 
openings). Behavioral baseline measurements were taken before injury, prior to and after 
intraperitoneal administration of drug or vehicle. The duration of each stimulus was 
approximately 3 s and the inter-stimulus interval was approximately 15 s. Withdrawal 
threshold was determined by sequentially increasing and decreasing the stimulus strength 
(“up and down” method), analyzed using a Dixon nonparametric test [17], and expressed as 
the mean withdrawal threshold.
In experiments conducted in Indianapolis, mechanical stimuli were applied with seven 
filaments, each differing in the bending force delivered (10, 20, 40, 60, 80, 100, and 120 
mN), and fitted with a flat tip and fixed diameter of 0.2 mm. The filaments were tested in 
order of ascending force, with each filament delivered for 1 second in sequence from the 1st 
to the 6th spot. The interstimulus interval was 10–15 seconds. The incidence of foot 
withdrawal was expressed as a percentage of six applications of each filament as a function 
of force. A Hill equation was fitted to the function (Origin version 6.0, Microcal Software) 
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relating the percentage of indentations eliciting a withdrawal to the force of indentation. 
From this equation, the threshold force was obtained and defined as the force corresponding 
to a 50% withdrawal rate [52].
2.12. Osmotic minipump delivery
All drugs or saline being studied were delivered by means of an osmotic minipump (model 
AP 2001D; nominal pump rate: 8 μl/h for 1 day; model AP1003D: 1μl/h for 3 days; Alzet, 
Braintree Science, USA) that was primed according to manufacturers specifications and 
implanted subcutaneously on post-injury day 21. Briefly, after having shaved the skin, 
animals were anesthetized in an induction chamber with a volatile anesthetic in oxygen 
(isoflurane 4%). Anesthesia was maintained in a semi-open system using a nose-cone 
(isoflurane 2%). The minipump was inserted through a transversal incision in the skin of the 
lower middle part of the back, its aperture directed towards the head. Immediately after 
implantation, animals were allowed to recover from anesthesia. Behavioral testing for 
animals subjected to the 24 h minipumps began 1 hour after pump implantation and was 
repeated at 2, 4, 8, 24, 25, 26, 28, and 32 h. Behavioral testing for animals subjected to 72 h 
minipump began 8 hour after pump implantation and was repeated at 10, 12, 24, 36, 48, 60, 
72, 80 h. R9-CBD3-A6K was delivered at a doses of 0.17 mg/h (24 h pump) or 0.22 mg/h 
(72 h pump). Control minipumps that were implanted in injured animals delivered 0.12 ml 
of 0.9% NaCl/rat per day.
2.13. In vivo microdialysis to measure dopamine release from nucleus accumbens shell 
(NAc)
2.13.1. Intracranial cannulation—Stereotaxic surgeries were performed in anesthetized 
rats (ketamine/xylazine 80/12 mg/kg, i.p.; Western Medical Supply, Arcadia, CA/Sigma, St. 
Louis, MO) according to the brain atlas. A single guide cannula (AG-8, EICOM, San Diego, 
CA) was implanted into the left NAc shell (AP: bregma +1.7 mm; ML: midline −1.0 mm; 
DV: skull−6.0 mm). Stainless steel dummy cannulas were inserted to keep the guide cannula 
free of debris. After surgery, rats were housed individually and allowed to recover for 7 
days. The placement of the guide cannula was verified histologically post hoc. Data from the 
animals with misplaced cannula were discarded (<5%).
2.13.2. In vivo microdialysis procedures—Microdialysis was done in awake, freely 
moving rats with sham surgery or with TNI [62; 93]. The microdialysis probe (AI-8-2, 
EICOM, San Diego, CA) was inserted into the NAc with 2 mm semipermeable membrane 
(MW cutoff: 20 kDa) projecting beyond the guide cannula and perfused at 2.0 μl/min with 
artificial cerebrospinal fluid (aCSF: 147.0 mM NaCl, 2.8 mM KCl, 1.2 mM MgCl2 and 1.2 
mM CaCl2). After a 90 min washout period, 2 baseline and 6 treatment fractions (30 min/
fraction) were collected into pre-chilled (4°C) amber Eppendorf tubes containing 1.5 μl 40× 
antioxidant solution (6.0 mM L-cysteine, 2.0 mM oxalic acid and 1.3% w/v glacial acetic 
acid) [37]. All rats were then injected with cocaine (20 mg/kg, i.p.) and dialysates collected 
for additional 60 min as a positive control.
2.13.3. HPLC quantification of dopamine—Fractions were analyzed using Agilent 
1100 HPLC system (Agilent, USA) with a 5020 guard cell, MD-150 column and Coulochem 
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III 5014B electrochemical detector (Thermofisher; USA) at ambient temperature [93]. The 
guard cell was set at 350 mV, Electrode1 at −150 mV and Electrode2 at 250 mV. A standard 
curve was produced from 6 serial dilutions of DA (1.25 – 40 pg) in 20 μl aCSF plus 
antioxidant cocktail. The limit of detection (LOD) and limit of quantification (LOQ) were 
calculated according to the formulas: LOD = 3.3 (SDr/S); LOQ = 10 (SDr/S); where the 
standard deviation of the response SDr (SD of y-intercepts of regression lines) and the slope 
of the standard curve S were determined from the measurements of 10 independent standard 
curves. The LOD and LOQ for DA were determined to be 0.3 and 0.9 pg on column, 
respectively. The linearity of DA peaks was also validated. The integration of the DA peaks 
from HPLC chromatograms was performed by an experimenter blinded to the treatment 
groups.
DA concentrations in microdialysates were expressed as pg/μl. The percent change of the 
corresponding baseline level was calculated to normalize the variations of individual rats and 
allow for multiple comparisons. The data of Percent Change from Baseline (PCB) were then 
converted to area under the time effect curve (AUC) to reflect the integrated change of the 
treatments. Rats that had basal DA levels below LOQ in the dialysates, incorrect cannula 
placement, uneven baselines (defined as >50% difference in DA concentrations between the 
two baseline fractions), or failed to demonstrate an increase of > 100% over baseline levels 
post cocaine administration were excluded from data analysis (approximately 10%).
2.14. Assessment of abuse liability
Potential abuse liability was assessed with place conditioning in naïve rats as previously 
described [29; 48]. Three-chambered rat-CPP apparatus (San Diego Instruments, San Diego, 
CA) with the following modifications were used: (1) end chamber of horizontal black and 
white striped walls, smooth floor; (2) end chamber of black walls, rough floor; and (3) 
middle chamber of neutral gray walls and metal rod flooring. Female Sprague-Dawley rats 
(200–225 g, Harlan) were implanted with intracerebroventricular cannula (i.c.v.). Although 
we have previously observed penetration of tat-CBD3 into the brain after an intraperitoneal 
injection [13], here we chose the i.c.v. route so as to allow for the assessment of direct 
actions of the peptides on CNS regions associated with reward pathways. After a recovery 
period (7 days), rats were put in CPP boxes for 20-minute sessions and allowed to freely 
explore 2 end chambers and a middle transition zone with unique environmental cues in 
each end chamber. Baseline measurements were obtained for each rat on days 1 through 4. 
The average baseline per rat was determined across days and used to calculate the mean time 
spent in each chamber. Animals spending more than 80% of the total time in any chamber at 
baseline were excluded from the study. On days 5, 7, 9, 11, and 13, R9-CBD3-A6K (10 mg 
in 5 μL, i.c.v.) was paired with one of the end chambers, whereas rats were confined to that 
chamber for 20 minutes. On days 6, 8, 10, and 12, animals received an injection of vehicle 
(saline 5 mL, i.c.v.) paired with the opposite chamber. On days 13 to 14, in a peptide-free 
state, the total time spent by the rat was recorded and compared with baseline values for 
each chamber (paired t test). Preference was demonstrated if there was a significant increase 
in the total time spent in the conditioning chamber when compared to baseline values.
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2.15. Assessment of potential CNS side effects
2.15.1. Light-Dark Box test as a measure of anxiety-associated behavior—For 
the light-dark box test (LDBT), there were two adjoined light and dark compartments boxes 
with a 7 cm square opening to allow mice to move between them. The black box was 
covered (20cm×40cm×30cm height) and the white box (20cm×40cm×30cm height) was 
open and illuminated (40 W). Each mouse was placed into the white compartment and the 
white compartment was video recorded for later analyses using ANY-maze software 
(version 4.75, Stoelting, Wood Dale, IL) which is a video tracking system designed to 
automate testing in behavioral experiments. The main parameters were duration of time 
spent in the light box; the latency to enter the dark box; and the number of transitions 
between the light and dark box.
2.15.2. Open-field test as a measure of anxiety-associated behavior—The open-
field arena covered an area of 90 cm × 90 cm, with 40 cm high walls. The open-field arena 
was divided into a 6 × 6 grid of equally-sized squares using black tape (36 total squares) 
with 4 squares forming the center; 12 squares forming the middle perimeter; and 20 squares 
forming the outer perimeter. The test started by placing a rat in the center. The behavior of 
each mouse in the open-field arena was recorded on video and scored afterwards by an 
observer blind to the experimental treatment of each rat. Time spent in each region of the 
open-field was recorded.
2.15.3. Elevated plus maze (EPM) anxiety test as a measure of anxiety-
associated behavior—Immediately following the LDBT, rats were place in the center 
area of the EPM where the two arms intersect. The EPM measures many relevant anxiety 
related behaviors such as: number of pokes and full entries into and duration spent in closed 
versus open arm. The arena dimensions are the following: each arm is 5 cm wide and 35.5 
cm long, closed walls are 15 cm high. The arms and central platform of the apparatus are 
elevated to a height of 62 cm. Behavior was video recorded for later analyses using ANY-
maze software (version 4.75, Stoelting, Wood Dale, IL) which is a video tracking system 
designed to automate testing in behavioral experiments. The main parameters were duration 
of time spent in the open and closed arm and number of entries into the arms.
2.15.4. Tail suspension test as a measure of depression-associated behavior
—Immediately following the EPM test, the TST was conducted according to standard 
procedure [23] between 8:00 AM and 2:00 PM. Briefly, each mouse was suspended by the 
tail at a height of 40 cm by taping the rail to a horizontal bar so that the tail is vertical to the 
bar. Behavior was video recorded for 5 min and later analyzed by an experimenter who was 
blinded to the treatments. An animal was considered to be immobile when it did not show 
any movement and hanged passively. If a mouse climbed its tail the mouse was gently pulled 
back down and continue trial. Mice that climbed their tails for more than 20% of the trial 
(i.e. >60 seconds) were eliminated from the final analysis. Duration and frequency of 
immobility were the main parameters measured.
2.15.5. Novel object recognition test—The experimental apparatus consists of an 
open-field box (36 × 30 × 26 cm). The apparatus was located in a quiet room. All mice were 
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subjected to three phases: acclimation, acquisition and test, and scores were recorded. For 
acclimation, the mouse was placed into the open field box and allowed to explore freely for 
10 minutes daily for three days. No objects were placed in the box during the acclimation 
trial. Following acclimation, the acquisition trial was conducted by placing the mouse in the 
field; two novel objects are symmetrically fixed to the floor of the box 5 cm from the walls. 
The objects were constructed from a ping-pong ball, a cylindrical bottle cover and a piece of 
Lego brick, which were different in shape and color but similar in size. Mice were allowed 
to explore the two objects for 10 minutes (day 4), and exploratory activity (i.e., the time 
spent exploring each object) was recorded. After 24 hours (day 5), mice are re-exposed to 
one of the objects of the acquisition phase, together with a novel object (not used in 
acquisition phase). Once again, animals were allowed to explore freely for 5 minutes and the 
time spent exploring each object is recorded. A mouse was considered to be involved in 
exploratory behavior when its head was oriented directly towards the object and within 
approximately 1–2 cm from it. For test data, the percentage of exploration time spent at the 
novel object was determined.
2.16. Statistical analyses
Differences between means were compared by either paired or unpaired two-tailed Student’s 
t–tests. Behavioral threshold values were statistically analyzed for each foot separately and 
the significance of differences between the average of at least two pre-injection tests and the 
mean obtained for each post-injection test. In all tests, baseline data were obtained for the 
TNI-injured groups before drug or vehicle administration. Within each treatment group, 
post-administration means were compared with the baseline values by repeated measures 
analyses of variance (RMANOVA) followed by post hoc Tukey’s multiple comparison test. 
One-way ANOVA post hoc Tukey’s multiple comparison test was used to analyze the 
integrated area under the time effect curve (AUC) of microdialysis data. A p value of <0.05 
was used to indicate statistical significance between treatment and non-treatment groups.
3. Results
3.1. Rationale for choice of R9-CBD3-A6K for studies
We previously reported that CBD3, a 15 amino acid fragment of CRMP2, disrupts the 
CRMP2–CaV2.2 interaction [13] irrespective of the cell penetrating motif it is appended to: 
the HIV-1 transactivator of transcription domain (TAT) [13], a myristate (Myr) tag [29], or 
homopolyarginine (R9) [42]. A point mutation within the CBD3 sequence that replaced the 
alanine residue at position 6 with a lysine (i.e., A6K), increased binding to CaV2.2 and 
displayed increased structural stability compared to wild type CBD3 peptide as assessed 
from peptide array and molecular dynamics simulations, respectively [67]. Importantly, R9 
conjugated CBD3 reversed TNI-induced mechanical hypersensitivity [42]. Additionally, 
compared to wildtype CBD3, the A6K mutant version of CBD3 conjugated to TAT exhibited 
a greater propensity to reduce mechanical hypersensitivity induced by antiretroviral therapy 
[67]. These results provide a rationale for the testing of a novel peptide, R9 grafted onto the 
A6K mutant version of CBD3, to generate R9-CBD3-A6K, with the expectation that this 
chemical modification would result in superior cell-penetrating prowess of R9 [87] 
combined with the enhanced inherent stability of the A6K mutation [67] and its superior 
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anti-nociceptive potential [42] would produce a better antinociceptive peptide therapeutic 
compared to wildtype CBD3. We selected R9-CBD3-A6K here because of the reported 
ability of the A6K mutation to additionally affect R- and T-type calcium channels [67]. Both 
R- and T-type channels are important pain targets with R-type knockout mice exhibiting 
reduced responses to inflammatory pain [73] and antagonism of R- and T-type channels with 
small molecules resulting in reversal of neuropathic pain [25; 54]. Scramble and random 
sequence based peptides conjugated to various cargoes as controls have been previously 
studied as controls in molecular, biochemical and behavioral assays and shown to have no 
effects [13; 29; 42; 67].
3.2. R9-CBD3-A6K disrupts the CRMP2–CaV2.2 interaction and inhibits surface trafficking 
of CaV2.2 in DRGs
We previously showed that all cell penetrant forms of CBD3 inhibited the CRMP2–CaV2.2 
interaction [13; 29; 42; 67]. Therefore, we first confirmed that the R9-CBD3-A6K could 
interfere with the CRMP2–CaV2.2 interaction. Rat spinal cord lysates were incubated with 
glutathione beads pre-adsorbed with purified CRMP2-GST in the presence of DMSO (0.3%, 
control) or increasing concentrations (1–100 μM) of R9-CBD3-A6K and then the CRMP2-
bound proteins were recovered by boiling in Laemmli buffer in reducing conditions, 
followed by immunoblotting. Probing of the CRMP2-enriched fraction with a CaV2.2 
antibody demonstrated a robust interaction between CaV2.2 and CRMP2 (Fig. 1A; top blot, 
lane 2). R9-CBD3-A6K, in a concentration-dependent manner, attenuated this interaction 
with greater than ~75% inhibition at 10 μM (Fig. 1A; top blot and Fig. 1B). These results 
demonstrate that the R9-conjugated mutant peptide retains its ability to efficiently uncouple 
the CRMP2–CaV2.2 interaction.
We previously demonstrated that overexpression of a plasmid expressing the CBD3 
fragment of CRMP2 almost completely prevented surface expression of co-expressed 
CaV2.2 in a surrogate neuronal cell line [13]. Confocal microscopy confirmed that both 
TAT- and Myr-conjugated CBD3 peptides inhibited surface trafficking of CaV2.2 in DRGs 
[29]. Here, we asked if R9-CBD3-A6K could affect trafficking of CaV2.2 in live DRGs in 
culture. Acutely dissociated DRGs grown for 12 h in culture were incubated in the absence 
(control) or presence of increasing concentrations of R9-CBD3-A6K (1 to 100 μM) for 24 h 
and surface biotinylated proteins were enriched using streptavidin beads. CaV2.2 was 
detected in the streptavidin-enriched biotinylated fractions (Fig. 1C; top blot, lanes 1–7) with 
little to no detection of the cytosolic protein βIII-tubulin in these fractions verifying the 
integrity of the extracellular biotinylation (Fig. 1C; third blot from top, lanes 1–7). CaV2.2 
surface expression was calculated as the ratio of the biotinylated to total CaV2.2 and then 
normalized to the neurons treated with control. R9-CBD3-A6K, in a concentration-
dependent manner, reduced the surface fraction of CaV2.2 with ~70% inhibition at 3 and 10 
μM (Fig. 1C, D; top blot, lanes 3 and 4 compared to lanes 1 or 7). Increasing the 
concentration beyond 30 μM did not have any further inhibitory effects.
Next, we used immunofluorescent microscopy to determine if R9-CBD3-A6K affected the 
subcellular localization of both proteins. Sensory neurons were incubated with R9-CBD3-
A6K peptide for 30 min and examined for their labeling of CaV2.2 and CRMP2 with 
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specific antibodies. Visual inspection of the micrographs (Fig. 1E) demonstrated that, in 
control cells treated with vehicle, the fluorescent signals for both proteins appeared to 
overlap at the plasma membrane of the DRGs. As illustrated in Fig. 1E (top right panel), 
prominent CaV2.2 staining was observed within the membrane in the absence of peptide and 
this staining co-localized with CRMP2 (Fig. 1E, top left panel). The Pearson correlation 
coefficient (PCC) was used to quantify the degree of colocalization between the 
fluorophores for the two proteins; PCC relies on the deviation from the mean. The high PCC 
values verified the membrane colocalization (Fig. 1F). After 30 min of R9-CBD3-A6K 
peptide treatment, CaV2.2 labeling was largely absent from the membrane (Figs. 1E, lower 
right panel; Fig. 1F) in contrast to DMSO-treated cells (Figs. 1E, lower left panel; Fig. 1F). 
Taken together, these results suggest that biochemically, R9-CBD3-A6K’s mechanism of 
action is to uncouple the CRMP2-CaV2.2 complex and prevent CaV2.2 from being targeted 
to the DRG neuronal membrane.
3.3. R9-CBD3-A6K inhibits K+-evoked Ca2+ influx in sensory neurons
We previously reported that uncoupling the CaV2.2–CRMP2 interaction with TAT- [13] or 
R9-CBD3 [42] resulted in a reduction of depolarization-induced Ca2+-influx in sensory 
neurons. Here, we asked if R9-CBD3-A6K could work similarly. Calcium imaging 
experiments performed with Fura-2AM on rat DRG neurons demonstrated that stimulation 
with high 90 mM KCl (a concentration at which only CaV2 channels are recruited [88]) 
produced a transient rise in intracellular calcium ([Ca2+]c) (Figure 2A). Peak calcium influx 
was recorded within 20 sec of stimulation (Fig. 2A, B). Calcium responses of DRGs, of 
small to large diameter neurons, incubated for 20 min with R9-CBD3-A6K were reduced, by 
~50% in their peak (Fig. 2B, C) or integrated area under the curve (AUC) compared to 
control (Fig. 2D). These results demonstrate that R9-CBD3-A6K inhibits calcium influx via 
CaV2 channels (see also section 3.6.).
3.4. Functional ‘fingerprinting’ of sensory neurons treated with R9-CBD3-A6K reveals lack 
of off-target effects
Since R9-CBD3-A6K is a novel peptide, we set out to address to its potential side effects 
using a recently described phenotypic screening method termed constellation pharmacology 
[79; 80], which uses subtype-selective pharmacological agents to elucidate cell-specific 
combinations (constellations) of key signaling proteins that describe specific cell types. The 
constellation pharmacology protocol [57] consists of sequential challenges, applied 6-min 
apart, to test activity of Ca2+ permeable ligand-gated ion channels, metabotropic receptors 
and voltage-gated Ca2+ channels. At the end of each experiment, a membrane-depolarizing 
agent (i.e., KCl) is used to ensure neuronal viability; neurons that did not respond to this 
trigger were not analyzed. In each case the readout is a change in Ca2+ fluorescence. Typical 
responses to the challenges (Table 1) used are illustrated in Figure 3. Examples of typical 
Ca2+ traces of DRGs incubated with vehicle (0.002% DMSO) (Fig. 3A) or R9-CBD3-A6K 
(10 μM) (Fig. 3B) demonstrate the heterogeneity in responses. Importantly, consistent with 
our earlier data (Fig. 2), R9-CBD3-A6K reproducibly decreased the K+-evoked Ca2+ influx 
despite being applied after several challenges of the constellation pharmacology protocol.
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We applied the constellation pharmacology protocol [57] to DRG neurons treated for 30 min 
with 10 μM R9-CBD3-A6K (n=1301) or 0.002% DMSO (vehicle, n=1184) (Table 1). Data 
from 4 independent experiments were collected and the responses of each neuron to each 
constellation pharmacology trigger were analyzed. Only DRGs with responses >10% over 
the baseline fluorescence were considered in our analyses. We first asked if R9-CBD3-A6K 
treatment altered the overall competence of the neurons by assessing if the DRGs respond to 
the same number of agonist challenges, independently of which compound they responded 
to (Fig. 3C). In vehicle-treated DRGs, ~35% of cells responded to KCl only (labeled as 0 in 
radar plot in Fig. 3C), ~49% responded to KCl plus 1 other trigger (labeled 1 in Fig. 3C), 
and ~13% responded to KCl plus 2 other triggers (2 in Fig. 3C). The percent of neurons 
responding to more than 2 triggers was ≤ 3% (Supplementary Table 1). These percent 
responses were not altered by incubation with R9-CBD3-A6K (Fig. 3C, red lines), 
demonstrating that the peptide does not affect the overall capacity of sensory neurons to 
respond to agonist challenges.
We next asked if R9-CBD3-A6K could change the sensitivity of sensory neurons to the 
different agonist challenges. We determined the percent of cells responding to a defined 
trigger alone or to the defined trigger in combination with any other trigger(s). In vehicle-
treated DRGs, the percent responders to the various triggers were: ~26% (Acetylcholine 
(Ach)), 2% (allyl isothiocyanate (AITC)), 17% ATP, 3% histamine, 5% menthol, and 33% 
capsaicin (Fig. 3D and Supplementary Table 1). The percent responders to these agonists 
were unchanged in cells treated with R9-CBD3-A6K (p>0.05, z-test) (Fig. 3D). In addition 
to the above classes, other major neuronal populations were also unchanged by R9-CBD3-
A6K treatment (Fig. 3E and Supplementary Table 1). These results demonstrate that R9-
CBD3-A6K does not target distinct neuronal populations.
3.5. Functional ‘fingerprinting’ and radioligand binding assays demonstrate selectivity of 
R9-CBD3-A6K
The above analyses do not take into account the extent of inhibition of Ca2+ influx following 
each challenge. Therefore, here we analyzed peak Ca2+ responses of responders to the 
various triggers. Agreeing with the inhibition in K+-evoked Ca2+ influx observed in single 
trigger experiments earlier (Fig. 2), R9-CBD3-A6K again decreased K+-evoked Ca2+ influx 
(~44% reduction compared to control, p<0.001) (Fig. 3F). Notably, compared to vehicle-
treated neurons, the peak Ca2+ amplitude of R9-CBD3-A6K-treated DRGs was unchanged 
for all other triggers (p>0.05) except Ach (Fig. 3F). Area under the curve analyses of 
calcium influx (Fig. 3G) was similar to peak influx for all conditions except capsaicin: 
control 6.21 ± 0.35 (n=393) versus R9-CBD3-A6K 5.22 ± 0.27 (n=432). While this 
inhibition (~16%) is statistically significant and suggests a possible direct effect on vanilloid 
receptor 1 (VR1 or TRPV1), it may not be biologically relevant because of the differential 
access of capsaicin, a relatively hydrophobic molecule, across the lipid membrane. 
Additionally, because a previous study had reported that an arginine-rich hexapeptide blocks 
calcium influx via TRPV1 [36], we tested if the R9-CBD3-A6K peptide blocked these 
channels. Stimulation with 20 nM resiniferatoxin (RTX), a selective agonist of vanilloid 
receptors in nociceptive DRGs [16; 32; 91], induced a robust increase in [Ca2+]c in ~15% 
(19 of 126) DRGs. RTX-induced [Ca2+]c was unchanged in the presence of 10 μM of R9-
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CBD3A6K (p > 0.05; one-way ANOVA with Tukey’s post hoc test). Compared to vehicle-
treated neurons, the peak and AUC Ca2+ amplitude of R9-CBD3-A6K-treated DRGs was 
also changed for Ach (Fig. 3F, G), suggesting an action via G-protein couple receptors on 
nicotinic acetylcholine receptors.
Primary radioligand binding profiles were also determined for R9-CBD3-A6K against a 
panel of 56 receptors, ion channels, and transporters, including adenosine, angiotensin, 
cannabinoid, serotonin, adrenergic, dopamine, GABA, histamine, muscarinic, melanocortin, 
neurokinin, neuropeptide Y, opioid, sigma, and transporters, and we saw no significant 
binding at 10 μM of R9-CBD3-A6K (Supplementary Table 2). R9-CBD3-A6K exhibited 
modest binding (~50–64% displacement at 10 μM) for muscarinic, neurokinin, and 
neuropeptide Y receptors, the small conductance Ca2+-activated K+ (SKCa) channel, and 
norepinephrine and dopamine receptors (Supplementary Table 2).
Collectively, these results triangulate to identify R9-CBD3-A6K as a selective inhibitor of 
calcium influx via CaV2 channels.
3.6. R9-CBD3-A6K inhibits Ca2+ currents in sensory neurons
We previously reported that TAT-CBD3 inhibits N- [13] and T-type [67] Ca2+ currents in 
sensory neurons, while the mutant TAT-CBD3-A6K peptide additionally inhibits R-type 
Ca2+ currents as well [67]. Here, we examined the effects of R9-CBD3-A6K on Ca2+ 
currents in sensory neurons. Acute application (30 min) of the R9-CBD3-A6K peptide 
inhibited total Ca2+ currents by ~63% (Fig. 4A, B); no changes were observed in activation 
or inactivation of these currents (data not shown). A further isolation of the currents using 
pharmacological blockers and appropriate voltage protocols, as described previously [67] 
(see also Methods), revealed a significant reduction of both T- (by ~40% compared to 
control) and R-type (by ~39% compared to control) Ca2+ currents (Fig. 4B). A similar level 
of inhibition (~33%) was observed using calcium imaging experiments in DRG neurons 
where we isolated Cav3 (T-type) channels using toxins selective for the other channels 
(control: 1.29 ± 0.05 (n=189) versus R9-CBD3-A6K: 0.87 ± 0.06 (n=121). The decrement in 
currents caused by acute application of R9-CBD3-A6K sets it apart from the myristoylated 
version of the peptide [29] and gabapentin, both of which were reported to unsuccessful in 
blocking currents following acute treatments [34].
3.7. Acute R9-CBD3-A6K suppresses excitability of nociceptive DRG neurons
We previously demonstrated inhibition of both T- and R-type Ca2+ macroscopic currents in 
sensory neurons by TAT-CDB3-A6K Similarly, R9-CBD3A6K was able to inhibit non-L-
type, T- and R-type Ca2+ currents in DRG neurons (Fig. 4B). As both of these currents are 
important for controlling neuronal excitability [39; 55], we tested if R9-CBD3-A6K could 
affect neuronal excitability of dissociated DRG neurons. The excitability was measured by 
injecting current pulses (nA) into the soma of small diameter (≤30 μm) DRG neurons every 
30 seconds in order to elicit 4–6 action potentials (average current injection of 0.6 ± 0.1 nA 
(n=16)) under control conditions prior to the addition of peptides into the recording bath. 
Representative recordings (Fig. 5A) and grouped data (Fig. 5B) show that the excitability of 
small diameter DRG neurons was decreased by R9-CBD3-A6K in a concentration-
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dependent fashion. Five minutes following perfusion of R9-CBD3A6K, there was on 
average a ~85% reduction in the number of action potentials elicited by a current pulse 
compared to control (1.0 ± 0.3 (n=5) APs with 30 μM R9-CBD3A6K versus 6.7 ± 0.5 (n=5) 
APs with a vehicle control (*, p <0.05, Student’s t-test; Fig. 5B).
3.8. R9-CBD3-A6K suppresses TNI-induced mechanical hypersensitivity
Tibial nerve injury (TNI) induces robust, long-lasting mechanical hypersensitivity indicated 
by reduction of the tactile threshold in the ipsilateral hindpaw, which was reversed by an 
acute systemic administration of R9-CBD3A6K (20 mg/kg, intraperitoneal (i.p.)). A single 
injection of R9-CBD3-A6K produced significant reversal of the tactile threshold towards 
pre-injury baseline for at least 4 hours; the tactile sensitivity of naïve animals was unaffected 
by the peptide (Fig. 6A). This duration of reversal of mechanical allodynia is similar to what 
we observed with TAT-CBD3 [13], TAT-CBD3-A6K [67], or R9-CBD3 [42]. Here, we R9-
CBD3-A6K showed an extended duration of action by measuring reversal of mechanical 
allodynia following drug delivery via subcutaneous (s.c.) osmotic minipumps. Using 24 h 
minipumps, a 0.17 mg/h (4 mg/day, s.c.) dose started to produce significant anti-allodynic 
effects starting at 8 h post-initiation of the infusion (Fig. 6C). This effect lasted for about 4 
hours after termination of the infusion. Saline infusion did not alter TNI-induced mechanical 
hypersensitivity (Fig. 6B). Using 72 h minipumps, a 0.22 mg/h (~5.2 mg/day, s.c.) dose 
elicited a similar time-course of anti-allodynic effects starting at ~10 h post-initiation of the 
infusion and lasted for 62 h, indicating no tolerance was developed to this effect (Fig. 6D). 
These results demonstrate that the R9-CBD3-A6K peptide exhibits a long-lasting effect 
without the development of tolerance within the 72 h continuous infusion. In contrast, 
opiates such as morphine have been shown to elicit antinociceptive tolerance within 2–3 
days [38; 65; 92].
3.9. R9-CBD3A6K induces DA release from NAc in TNI, but not sham, animals
In addition to the efficacy of R9-CBD3A6K in abolishing evoked tactile hypersensitivity, we 
also examined the release of dopamine (DA) from nucleus accumbens (NAc) shell as a 
surrogate marker of relief of ongoing pain. Extracellular DA levels in the NAc shell were 
measured via in vivo microdialysis in awake rats. Basal NAc DA levels were not 
significantly different in sham-operated or tibial nerve-injured (day 14 post-injury) groups 
with 0.16 ± 0.05 and 0.10 ± 0.02 ng/ml, respectively (P = 0.184, unpaired t-test). We 
detected a significant increase of DA release in all 6 fractions (total 3 h) after an acute 
administration of R9-CBD3-A6K (10 mg/kg, i.p.) selectively in rats with nerve injury, 
consistent with its observed anti-allodynic actions (Fig. 7A). Importantly, the same dose of 
R9-CBD3-A6K had no effect in sham-operated animals suggesting limited abuse potential. 
The area under the time effect curve (AUC) also showed significantly higher levels of 
integrated DA release (Fig. 7B, P < 0.05 TNI/R9-CBD3-A6K vs. TNI/Vehicle or Sham/R9-
CBD3-A6K).
3.10. Lack of abuse liability by i.c.v. administration of R9-CBD3-A6K
Potential abuse liability of R9-CBD3A6K was further evaluated using conditioned place 
preference (CPP) in naïve rats. In order to ensure availability of the peptide to brain reward 
centers, R9-CBD3A6K was given by the intracerebroventricular (i.c.v.) route and the rats 
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were paired with a chamber for 5 exposures on consecutive days. The total time spent in the 
paired chamber was measured 24 hours after the final exposure on day 6, in drug-free 
animals (Fig. 8). At baseline, all rats spent 43% of the total time in the putative conditioning 
chamber over a 20-minute period (526.6 seconds; Fig. 8). Unlike our previous studies 
demonstrating that morphine (i.c.v. dosing) results in a positive condition place preference 
indicative of the potential of rewarding behavior [48], R9-CBD3-A6K (10 μg in 5 μL, i.c.v.) 
did not produce a significant increase in total time per chamber (45.7%; p = 0.76) nor a 
decrease suggesting lack of conditioned place aversion. These data suggest that R9-CBD3-
A6K acts neutrally at supraspinal sites and, in the absence of ongoing pain, does not produce 
rewarding or aversive behaviors.
3.11. Lack of off-target neurobehavioral effects following continuous systemic infusion of 
R9-CBD3-A6K
A battery of classic behavioral tests was carried out to detect any potential CNS deficits that 
might induced by chronic administration of R9-CBD3A6K in naïve mice and TNI rats (Fig. 
9). Anxiety occurs when there is conflict between risk and reward [50]. The Open-field test 
(OFT), Light-Dark Box test (LDBT) and the elevated plus maze (EPM) are accepted tests of 
anxiety-associated behavior that assess the conflict mice have against hiding in enclosed 
dark areas (i.e., dark box or closed arm) and their tendency to explore novel environments 
(i.e., white box or open arm) [9; 47]. These tests are also sensitive to anxiolytic drug 
treatments. Since rodents such as mice and rats display immobile postures when placed in 
inescapable stressful situations [18; 83], immobility behavior in the tail suspension test 
(TST) is used as a measure of “depression” or “despair” associated behavior. Furthermore, 
administering antidepressant treatments prior to testing reduces immobility behavior (see 
review [23]). Therefore, the TST is often used to screen novel drugs for depressant or anti-
depressant properties. Finally, the novel object recognition test is used to evaluate cognition, 
particularly recognition memory, in rodents [5]. This test is based on the spontaneous 
tendency of rodents to spend more time exploring a novel object than a familiar one. The 
choice to explore the novel object reflects the use of learning and recognition memory.
Injecting R9-CBD3-A6K (20 mg/kg, i.p.) 1 hr prior to testing did not alter behaviors in the 
EPM, and LDBT (Fig. 9A, B) measures of anxiety [50]. In the EPM (n=8,8), there were no 
differences noted in open arm time/entries (t(14)=−1.515, p=0.152/t(14)=0.590, p=0.565); 
closed arm time/entries (t(14)=0.495, p=0.628/t(14)=1.154, p=0.268); or intersection time/
entries (t(14)=1.750, p=0.102/t(14)=0.648. p=0.527). In the LDBT, neither the latency to enter 
light compartment (t(13)=1.231, p=0.240) nor the percentage of time spent in the light 
compartment (t(13)=1.079, p=0.300) were affected by R9-CBD3-A6K administration (n=7,8, 
one outlier removed from the vehicle group for being greater than 2 standard deviations 
away from the mean, Grubb’s test (critical z value = 2.13, p<0.05).
Fig. 9C shows the effect of R9-CBD3-A6K (20 mg/kg, i.p.) at 1 hr post-injection in the TST 
(n=8,8), where no change in immobility time was noted between treatment groups (t(14)= 
−0.204, p=0.841).
Fig. 9D shows the effect of R9-CBD3-A6K (20 mg/kg, i.p.) at 1 hr post-injection in the 
NORT (n=8,8), where both vehicle and R9-CBD3-A6K treated animals showed a similar 
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novelty preference [Object preference F(1,14)=10.5, p=0.006; but no treatment F(1,14)=0.5, 
p=0.475, or treatment × object preference noted F(1,14)=0.5, p=0.501].
Fig. 9E–F shows the effect of R9-CBD3-A6K (20 mg/kg, i.p.) at 1 hr post-injection in the 
OFT (n=8,8), where the R9-CBD3-A6K did not alter distance traveled (t(14)=0.831, 
p=0.420), stationary time (t(14)= −1.452, p=0.169), time freezing (t(14)= −1.444, p=0.171), or 
inner time (t(14)=1.642, p=0.123). R9-CBD3-A6K (~5.2 mg/day, s.c.) also did not alter 
distance traveled (F(2,6)=1.00, p=0.420), stationary duration (F(2,6)=3.5, p=0.098), or 
freezing duration (F(2,6)=4.8, p=0.056) when assessed on day 1 (i.e. pre-pump, when the rats 
exhibited mechanical hypersensitivity (Fig. 6D, yellow bar)), day 3 (at 48 h after the start of 
the minipump, when the mechanical hypersensitivity was completely reversed (Fig. 6D)) 
and day 4 (at 72 h after the start of the minipump, when the mechanical hypersensitivity was 
completely reversed (Fig. 6D)) (n=4). These times were chosen for the OFT as the peak of 
anti-nociception of R9-CBD3-A6K was at 12 h post-infusion with the minipump and 
remained stable for 60h (until hour 72 when the pump emptied), and likely corresponds to 
sufficient blood levels of R9-CBD3-A6K to produce anti-nociception. A difference in time 
spent in inner zone was reduced over time (F(2,6)=8.0, p=0.020) for TNI rats. While the 
reason for this was not investigated further, this is commonly observed when rodents are re-
exposed to same arena and it ceases to be novel [40].
4. Discussion
The data reported here demonstrate that R9-CBD3-A6K has pan-Ca2 interactions that result 
in reduced calcium influx and excitability of sensory neurons, as well as inhibition of 
mechanical hypersensitivity and relief of nerve-injury induced ongoing pain. R9-CBD3-
A6K was not intrinsically rewarding suggesting a lack of abuse liability and did not promote 
anxiety or depression or affect learning. Collectively, these data suggest the utility of this 
novel peptide for treatment of neuropathic pain.
Regulation of voltage-gated calcium channels has been clinically validated as a treatment for 
neuropathic and other types of pain. CaV2.2 (N-type) channels are highly expressed on 
nociceptive fibers within the dorsal horn of the spinal cord and essential in relaying pain 
signals from the periphery to higher centers. Alternative splice variants found on small 
diameter nociceptive neurons are associated with increased thermal and mechanical 
hyperalgesia [3; 8]. CaV2.2 is believed to be responsible for increased neurotransmitter 
release commonly associated with chronic and neuropathic pain conditions [43; 77; 96]. 
Consistent with the role of CaV2.2 in pain signaling, genetic deletion, as well as 
pharmacologic block of CaV2.2, impairs nociception [53; 71]. Additionally, central 
blockade of CaV2.2 is effective in treatment of cases of chronic pain that are intractable to 
other interventions [11]. Other subtypes of calcium channels, such as CaV2.3 (R-type) [54; 
72; 81] or CaV3 (T-type)[35; 51; 58], have also been indicated to play important roles in 
chronic pain. The CaV2.3-selective blocker, SNX-482, has been reported to block the C- and 
Aδ- fiber neurotransmission in animal models of chronic neuropathic pain [54] and reduce 
formalin induced paw-flinching and FOS-expression in the ipsilateral spinal cord [81]. 
CaV2.3 knockout mice have nociceptive deficits [72]. Low threshold CaV3.2-expressing C 
fibers have been shown to mediate cold allodynia in humans [74]. Therefore, inhibition of a 
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broad spectrum of VGCCs by R9-CBD3-A6K may exert synergistic effects among different 
calcium channel subtypes and underlie its potency and efficacy in ameliorating nerve injury-
induced neuropathic pain with improved therapeutic potential when compared to approaches 
aimed at complete blockade of an individual subtype, especially CaV2.2. Consistent with 
this possibility, R9-CBD3-A6K did not show any of the side effects associated with 
Ziconotide [68].
Pain in humans is multidimensional with sensory, affective (aversive) and cognitive 
components [27]. Preclinical assessment of pain has mainly employed measures of changes 
in sensory thresholds following induction of an injury [27]. While this approach has been 
valuable in exploring mechanisms underlying important clinical features of pain including 
allodynia, capturing affective (i.e., aversive) dimensions of pain that are important to patients 
in non-verbal animals has been challenging [33; 46; 60]. Our laboratory has evaluated pain 
motivated behavior and demonstrated that relief of ongoing pain is a natural reward that 
evokes DA release within the NAc [22; 59], consistent with human imaging studies [6; 7; 24; 
62; 93]. We proposed that release of dopamine in the NAc by intrinsically non-rewarding 
treatments in the setting of injury could represent a translational biomarker of pain relief 
[24; 62; 69; 93]. In the present study, our data show that R9-CBD3-A6K reverses evoked 
hypersensitivity in nerve-injured rats. Additionally, R9-CBD3-A6K increased DA release 
within NAc selectively in injured animals suggesting relief of pain aversiveness and 
consistent with our previous studies [61; 93]. It seems likely that the effects of R9-CBD3-
A6K on both evoked and ongoing pain may result from uncoupling of CRMP2 from calcium 
channels, limiting calcium influx into neurons to diminish nociceptive input and to activate 
dopaminergic circuits [4; 78].
It is important to note that R9-CBD3-A6K did not elicit DA release in sham-operated 
animals, suggesting the enhanced DA efflux in injured animals was due to relief of ongoing 
pain and not due to an intrinsic rewarding property of R9-CBD3-A6K. Conditioned place 
preference (CPP), another measure of relief of ongoing pain, was not used here as we have 
previously reported that there are parallel changes between dopamine release from NAc and 
the CPP difference score when underlying ongoing pain is present (see reference [93]).
The potential of R9-CBD3-A6K to penetrate into the brain also raises concerns of possible 
CNS side effects. Intrathecal ω-conotoxin can produce severe CNS side effects such as 
ataxia and confusion presumably since ω-conotoxin is redistributed to higher centers [2; 82]. 
However, we did not observe ataxia following R9-CBD3-A6K administration. The lack of 
CNS side effects was confirmed using a battery of behavioral tests designed to evaluate 
cognitive and emotional functions, including abuse liability, following acute and chronic R9-
CBD3A6K administration. R9-CBD3-A6K did not show any effects in the novel object 
recognition test suggesting no impact on learning and memory [30; 31]. In addition, the 
animals spent the same amount of time in the light box (light dark box test) or open arm 
(elevated plus maze test) after R9-CBD3A6K or vehicle (saline) treatment, suggesting no 
alterations in the anxiety levels by R9-CBD3A6K administration. Furthermore, there were 
no distinguishable differences in reaching immobility during the tail suspension test, 
suggesting no change of depression score after R9-CBD3-A6K administration. Open field 
test results also showed comparable distance travelled and exploration of the central area by 
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naïve or nerve-injured rats following 72 h continuous infusion of R9-CBD3-A6K, indicating 
no disruption of normal locomotion and sensory/motor functions post-sustained R9-CBD3-
A6K infusion. We further confirmed lack of abuse liability by five repeated exposures of R9-
CBD3-A6K by the intracerebroventricular route to naïve rats using the CPP paradigm. 
While drugs with intrinsic reward, such as morphine, reliably elicit place conditioning, R9-
CBD-3A6K had no effect. This finding suggests a lack of abuse liability and is consistent 
with the failure of the peptide to elicit NAc DA release in uninjured rats. This is particularly 
important for new analgesics developed to treat chronic pain on a daily basis in light of the 
ever rising concerns of prescription drug abuse and overdose [1]. These results confirm a 
lack of CNS side effects with R9-CBD3-A6K treatment.
Collectively, our data support the conclusion that targeting protein interactions that regulate 
voltage-gated calcium channels is a promising strategy for pain relief with multiple 
advantages over direct channel block. Thus, while similar levels of efficacy can be achieved 
by targeting channel regulation compared to channel function, this approach appears to 
avoid many of the adverse side effects associated with direct channel block. We have 
discovered a novel CRMP2 peptide R9-CBD3-A6K that provides excellent efficacy in 
relieving neuropathic pain. R9-CBD3-A6K does not target specific sensory neuronal 
subtypes as assessed by constellation pharmacology and produces uniquely long-lasting 
efficacy. Future studies will use pharmacophore modeling to design small molecule 
peptidomimetics of CBD3 that may be similarly effective. In conclusion, our results from 
previous and current studies demonstrate that allosterically targeting CRMP2 interactions 
with different voltage-gated calcium channel subtypes represents a plausible strategy to 
ameliorate nerve injury-induced neuropathic pain in humans.
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Figure 1. R9-CBD3-A6K peptide inhibits the CaV2.2–CRMP2 interaction to decrease surface 
CaV2.2
(A) Spinal cord lysates were incubated with recombinant CRMP2-GST protein (0.4 μM) in 
the absence (0.1% DMSO, lane 2) or presence of increasing concentrations (as indicated) of 
peptide. The CRMP2-GST bound proteins were recovered by incubation with glutathione 
sepharose beads and immunoblotted with CaV2.2 (top) and CRMP2 (bottom). 
Representative blots from 3 separate experiments are shown. (B) Summary of mean relative 
binding of CaV2.2 to CRMP2. CaV2.2-CRMP2 binding was reduced by R9-CBD3-A6K in 
a concentration-dependent manner (*, p <0.01; one-way ANOVA with Tukey’s post-hoc 
test). n = 3 separate, individual experiments. (C) Cell–surface expression of CaV2.2 was 
monitored using a biotinylation assay. Acutely isolated DRGs cells, incubated with no 
peptide (control) or increasing amounts of R9-CBD3-A6K peptide, were biotinylated, the 
cell-surface proteins were harvested from the cell lysates, and the precipitates were analyzed 
by immunoblotting with CaV2.2 (top 2 blots) and βIII-tubulin (bottom 2 blots) antibodies. 
Equal amounts of samples were used for the precipitation of biotinylated proteins. Of these 
samples, the entire biotinylated fraction (surface) and 10% of the non-biotinylated (total) 
fraction were loaded. R9-CBD3-A6K decreased the amount of CaV2.2 at the cell surface 
compared to peptide-treated neurons. No change was observed in the total levels of CaV2.2 
or tubulin. Representative blots of surface biotinylated and total fractions immunoblotted 
with a CaV2.2 antibody (top) or tubulin (bottom) are shown (n = 3 separate, individual 
experiments). (D) Averaged CaV2.2 surface expression, normalized to total CaV2.2 and then 
to total tubulin (*, p <0.05; one-way ANOVA with Tukey’s post-hoc test). (E) 
Representative micrographs of DRG cells immunolabeled with CRMP2 and CaV2.2. The 
neurons are treated with 0.1% DMSO or with R9-CBD3-A6K (30 μM) for 48 hrs. Control 
cells not treated with the peptide display an overlap in membrane labeling of both CaV2.2 
and CRMP2. At 48 hrs CaV2.2 and CRMP2 labeling is scattered in distinct puncta within 
the cytosol. Scale bar length is 10 μm. (F) Quantification of colocalization of CaV2.2 with 
CRMP2 was carried using Pearson’s overlap method. The values in the graph are the overlap 
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coefficients. n = 2 separate, individual experiments; the total number of cells analyzed is 14–
17 per condition.
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Figure 2. R9-CBD3-A6K inhibits K+-stimulated Ca2+ influx in DRG neurons
Differential interference contrast (DIC) and pseudocolored fluorescent images of a field of 
DRG neurons visualized for Fura-2, before and after stimulation with KCl (A). Ca2+ 
imaging was performed on adult rat DRG neurons using the ratiometric Ca2+-sensitive dye 
Fura-2. Following a 1 min baseline measurement, neurons were stimulated with 90 mM KCl 
for 30–40 sec to induce Ca2+ influx. (B) Line graph shows the peak calcium influx 
(fluorescence response adjusted for background) over time of DRGs incubated for 20 min 
with 30 μM R9-CBD3-A6K was reduced to about 40% of that of untreated DRGs. Peak 
calcium influx (C) and integrated area under curve (AUC, D) also shows significant 
reduction of the calcium influx with pretreatment of R9-CBD3-A6K ((*, p <0.01; Student’s 
t-test). Values represent the average ± SEM from three separate imaging experiments from 
>100 cells per condition.
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Figure 3. Functional ‘fingerprinting’ of DRG neuronal subclasses following treatment with R9-
CBD3-A6K
(A) Ca2+-imaging traces of DRGs responding to constellation pharmacology agonist or 
membrane-potential triggers. Each trace represents the response of a different neuron. In a 
typical experimental trial, the responses (filled brown circles) of >100 individual neurons 
were monitored simultaneously. Selected traces are shown. The abbreviations used are 
defined in Table 1. Colored columns indicate the ~15-s application of challenge compounds 
or high [K+]o; after each application the free compound or high [K+]o was continuously 
washed out of the well with room-temperature bath solution. The y-axis shows the 
Fura-2AM fluorescence ratio (F340/F380) for each trace. Raw, unfiltered traces are presented. 
Triggers used were: menthol (400 nM), histamine (50 μM), ATP (10 μM), AITC (200 μM), 
acetylcholine (1 mM), capsaicin (100 nM) and KCl (90 mM). DRG neurons were treated 
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with either vehicle (0.002% DMSO) (A) or R9-CBD3-A6K (B) and the neuronal 
populations analyzed by the constellation pharmacology protocol. All cells were selected 
based on their response to the depolarizing pulse of KCl. Size of each cell is indicated by the 
surface area value in each trace. (C) The response of DRG neurons to one or more 
constellation pharmacology trigger was analyzed. The polar plot indicates the percentage of 
cells that responded to the indicated number of triggers independently of which compound 
they responded to. The number 0 corresponds to the proportion of cells that responded to 
KCl only and no other trigger. No significant change was observed in each category of cells 
after treatment with (S)-LCM. (D) Polar plot showing the percent of cells responding to each 
constellation pharmacology trigger independently of any other trigger that the cell also 
responded to. Each axis shows a different trigger. (E) Polar plot showing the percent of cells 
responding to major classes of triggers. Data are from 3 independent experiments with a 
total n=1184 for control and n=1301 for 10μM R9-CBD3-A6K. (F) Bar graph showing the 
average peak (F) or area under the curve (AUC) (G) calcium response in the major 
functional neuronal populations identified in (D). AUC was calculated with Prism software 
using the trapezoid rule. R9-CBD3-A6K did not decrease the peak calcium influx in 
response to any trigger except Ach and KCl for peak or Ach and Cap for and AUC (*, 
p<0.05; Student’s t-test). An AUC for KCl was not calculated in these experiments since 
KCl was the last trigger (see traces in A and B). (H) Heatmap of the size distribution of 
neurons responsive to the conditions show in D.
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Figure 4. Acute application of R9-CBD3-A6K decreases Ca2+ currents in sensory neurons
(A) Representative family of current traces are illustrated for control- (0.002% DMSO) or 10 
μM R9-CBD3-A6K-treated neurons. Currents were evoked by 200 millisecond prepulses 
between −90 mV and +60 mV. (B) Summary of the peak current density (pA/pF) from 
sensory neurons in the absence or presence of 10 μM R9-CBD3-A6K for total (left), T-type 
(middle), and R-type (right) Ca2+ currents. Calcium channel subtypes were isolated using 
pharmacological blockers and appropriate voltage protocols, as described previously [67]. 
n=11–18 cells for control and n=12–19 cells for 10 μM R9-CBD3-A6K-treated cells; 
asterisk indicates statistical significance compared with control cells (p<0.05, Student’s t-
test).
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Figure 5. R9-CBD3-A6K peptides reduce the excitability of DRG neurons
Current clamp recordings were performed on small-to-medium (>30 μm – >40 μm, 
measured via a reticle) diameter lumbar 4–5 DRG neurons from naïve rats. Firing of 4–6 
action potentials (APs) was elicited by a 1 second depolarizing current injection (ranging 
from 0.1 to 0.4 nA depending on the cell) every 30 seconds. (A) Representative recordings 
demonstrating that a concentration-dependent reduction in the number of elicited APs 
following application of 10 μM R9-CDB3-A6K. (B) Group data showing that R9-CBD3-
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A6K caused a significant reduction in DRG action potential firing (*, p<0.05 versus control, 
Student’s t-test; n=6–8 each).
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Figure 6. Acute and sustained administration of R9-CBD3-A6K reverses tibial nerve injury 
(TNI)-induced mechanical hypersensitivity
Paw-withdrawal thresholds (PWT in millinewtons, mN) were measured in nerve-injured rats 
before and after administration of R9-CBD3-A6K. PWT in rodents subjected to TNI was 
significantly reduced when compared to pre-surgery baseline at D14 post-TNI (n=6; white 
bar). (A) R9-CBD3-A6K, given as a bolus injection (20 mg/kg, i.p.), significantly reversed 
mechanical hypersensitivity at 1, 2 and 4 h post-dosing. (B) Tactile hypersensitivity of TNI 
rats was not lessened by chronic infusion of saline via an osmotic minipump. (C) Chronic 
administration of R9-CBD3-A6K (0.17 mg/h, s.c.) via an osmotic minipump, for 24 h, 
abolished the TNI-induced tactile hypersensitivity starting at 8 h post-dose and lasting for an 
additional 4 h after cessation of the pump. (D) Sustained administration of R9-CBD3-A6K 
(0.22 mg/h, s.c.) via osmotic minipump, for 72 h, provided continuous suppression of tactile 
hypersensitivity induced by TNI without any signs of development o tolerance. Mechanical 
hypersensitivity was assessed using the calibrated Von-Frey filaments. Behavior was tested 
at multiple time points indicated in the bar graphs. (*, p<0.05 compared to pre-dose (post-
injury) baseline, One-way ANOVA with Dunnett’s post hoc test). n=6 rats per condition.
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Figure 7. R9-CBD3-A6K induces dopamine (DA) release from nucleus accumbens (NAc) in TNI 
rats
(A) Extracellular DA levels in the NAc shell were measured via in vivo microdialysis in 
awake rats. Increase of DA release in all 6 fractions (total 3 h) after an acute administration 
of R9-CBD3-A6K (10 mg/kg, i.p.) was detected in rats with nerve injury (n=9). Vehicle 
administration did not produce any effect in rats with TNI (n=6). The same dose of R9-
CBD3-A6K given to the sham-operated rats did not produce any effect (n=4). (B) The area 
under the time effect curve (AUC) also showed significantly higher levels of integrated DA 
release in TNI rats after R9-CBD3-A6K administration (*, p<0.05 comparing TNI/R9-
CBD3-A6K vs. TNI/Vehicle or Sham/R9-CBD3-A6K, One-way ANOVA with Dunnett’s 
post hoc test).
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Figure 8. Absence of abuse liability by i.c.v. administration of R9-CBD3-A6K
Conditioned place preference (CPP) was used to determine the drug abuse liability of R9-
CBD3-A6K. At baseline, all rats were allowed to explore all 3 chambers over a 20-minute 
period (total 1200 seconds). The animals were then confined to one side paired with drug 
administration and then the next day the opposite side paired with vehicle treatment for 30 
min each. Total 5 exposures per treatment. 24 hours after the final exposure, all rats were 
allowed to explore all 3 chambers again and the total time spent in drug-paired chamber was 
measured in drug-free animals. R9-CBD3-A6K (10 μg in 5 μL, i.c.v.) did not produce any 
significant change in total time per chamber. (p>0.05 comparing baseline vs. test, Paired t-
test). n=10 rats per condition.
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Figure 9. R9-CBD3-A6K treatment does not have CNS side effects
(A) Elevated plus maze to evaluate anxiety-associated behaviors revealed that R9-CBD3-
A6K do not alter time spent or entries in the open, closed arms or intermediate zone. (B) 
Light dark box test to evaluate anxiety-associated behaviors revealed that R9-CBD3-A6K 
(20 mg/kg, i.p.) did not alter time spent in light box or latency to enter light box. (C) Tail 
suspension test of depression or despair-associated behaviors revealed that R9-CBD3-A6K 
(20 mg/kg, i.p.) did not alter the duration of immobility. (D) R9-CBD3-A6K (20 mg/kg, i.p.) 
and vehicle treated rodents both showed a similar preference for the novel object in a novel 
object recognition test. (E) R9-CBD3-A6K (20 mg/kg, i.p.) did not alter behaviors in an 
open field test (OFT) (n=8,8 for A-E). (F) R9-CBD3-A6K (~5.2 mg/day, s.c.) did not alter 
any behavior in a repeated daily (days 1, 3, 4) OFT in tibial nerve injury (TNI) rats with 
mechanical hypersensitivity, other than a decrease in time spent in the inner zone of OFT 
due to a reduction in novelty, n=4. Day 1 is the pre-pump day, when the rats exhibited 
mechanical hypersensitivity (see Fig. 6D, yellow bar)), day 3 is at 48 h after the start of the 
minipump, when the mechanical hypersensitivity was completely reversed (see Fig. 6D) and 
day 4 is at 72 h after the start of the minipump, when the mechanical hypersensitivity was 
completely reversed (see Fig. 6D).
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